CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue:
Total revenue	$ 13,196	$ 14,257
Expenses:
Research and development (1)	23,253	67,599
Selling, general and administrative (1)	19,121	30,550
Restructuring and related expenses	9,324
Total expenses	51,698	98,149
Total share-based compensation expense	14,545	15,832
Loss from operations	(38,502)	(83,892)
Income from investment in TRC, LLC	25,110	16,547
Interest expense	(11,655)	(11,873)
Interest and other income, net	(375)	(234)
Loss before income taxes	(25,422)	(79,452)
Provision for income tax benefit	(524)	(227)
Net loss	(25,946)	(79,679)
Net unrealized loss on available-for-sale investments	(28)	(30)
Total comprehensive loss	$ (25,974)	$ (79,709)
Net loss per share:
Basic net loss per share	$ (0.34)	$ (1.24)
Diluted net loss per share	$ (0.65)	$ (1.24)
Shares used to compute basic net loss per share	75,247	64,493
Shares used to compute diluted net loss per share	75,247	64,493
Research and development
Expenses:
Restructuring and related expenses	$ 4,700
Total share-based compensation expense	4,530	$ 7,921
Selling, general and administrative
Expenses:
Restructuring and related expenses	4,600
Total share-based compensation expense	5,498	7,911
Restructuring and related expenses
Expenses:
Total share-based compensation expense	4,517
Collaborative revenue
Revenue:
Total revenue	9	3,872
Licensing revenue
Revenue:
Total revenue	2,500
Viatris collaboration agreement
Revenue:
Total revenue	$ 10,687	$ 10,385